LMO4 mediates trastuzumab resistance in HER2 positive breast cancer cells
Authors:
- 1 January 2018
- journal article
- research article
- Vol. 8 (4) , 594-609
Abstract
Breast cancer is the leading cause of cancer-related mortality in women worldwide. Trastuzumab (Herceptin) is an effective antibody drug for HER2 positive breast cancer; de novo or acquired trastuzumab resistance retarded the use of trastuzumab for at least 70% of HER2 positive breast cancers. In this study, we reported LMO4 (a member of LIM-only proteins) promoted trastuzumab resistance in human breast cancer cells. Over-expression of LMO4 was observed in acquired trastuzumab resistance breast cancer cells SKBR3 HR and BT474 HR. Depletion of LMO4 partly abolished the trastuzumab resistance of SKBR3 HR and BT474 HR cells. Forced expression of LMO4 significantly increased trastuzumab resistance of HER2 positive breast cancer cells both in vitro and in vivo. BCL-2 was regulated by LMO4 and mediated the promoting role of LMO4 in trastuzumab resistance of HER2 positive breast cancer cells. High level of LMO4 was associated with worse clinicopathological parameters (including tumor size and histological grade) and lower survival rate in HER2 positive breast cancer patients. LMO4 therefore could be used as a target to develop diagnostic and therapeutic methods for human HER2 positive breast cancer.Keywords
This publication has 52 references indexed in Scilit:
- The oncoprotein HBXIP activates transcriptional coregulatory protein LMO4 via Sp1 to promote proliferation of breast cancer cellsCarcinogenesis, 2013
- Artemin Stimulates Radio- and Chemo-resistance by Promoting TWIST1-BCL-2-dependent Cancer Stem Cell-like Behavior in Mammary Carcinoma CellsJournal of Biological Chemistry, 2012
- Contribution of DEAF1 Structural Domains to the Interaction with the Breast Cancer Oncogene LMO4PLOS ONE, 2012
- Oncogenic LMO3 Collaborates with HEN2 to Enhance Neuroblastoma Cell Growth through Transactivation of Mash1PLOS ONE, 2011
- LMO4 expression in squamous cell carcinoma of the anterior tongueHistopathology, 2011
- Aberrant expression of LMO4 induces centrosome amplification and mitotic spindle abnormalities in breast cancer cellsThe Journal of Pathology, 2010
- LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progressionOncogene, 2009
- LIM only 4 is overexpressed in late stage pancreas cancerMolecular Cancer, 2008
- LMO3 Interacts with Neuronal Transcription Factor, HEN2, and Acts as an Oncogene in NeuroblastomaCancer Research, 2005
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987